|4Dec 27, 4:05 PM ET

DRISCOLL JOSEPH 4

4 · Akoya Biosciences, Inc. · Filed Dec 27, 2022

Insider Transaction Report

Form 4
Period: 2022-12-22
DRISCOLL JOSEPH
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-12-22$0.44/sh+250,000$110,000262,500 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2022-12-22250,000110,958 total
    Exercise: $0.44Exp: 2029-05-02Common Stock (250,000 underlying)
Footnotes (1)
  • [F1]The option will be fully vested on 03/18/2023.

Documents

1 file
  • 4
    tm2233541-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT